Device Trial Radar · NCT02295891
Miradry Treatment for Focal Axillary Hyperhidrosis
Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
31
Actual
Start
Nov 2014
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 29 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary hyperhidrosis is a pathological condition characterized by the idiopathic and excessive secretion of sweat beyond normal physiological demand and is localized at particular foci such as the face, axilla, palms of the hands, and soles of the feet. Patients seeking medical attention for hyperhidrosis often report disruptions to their professional and/or social lives due to sweating and subsequently experience many psychosocial difficulties, such as anxiety, social phobia, and depression. Therefore, a psychiatric explanation of causality is frequently offered for these patients during diagnosis. Excessive sweating is often mistakenly interpreted as a symptom of an anxiety disorder and can be cause for social embarrassment, exacerbating emotional stress and social avoidance. As currently constituted, the treatment of secondary psychosocial symptoms in primary hyperhidrosis is poorly understood and requires further investigation.
Conditions
- Axillary Hyperhidrosis
Interventions
MiraDry ®Device
Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Severity as Assessed by the Hyperhidrosis Disease Severity Scale (HDSS)Time frame: Baseline, 6 months, 1 Year
- Quality of Life as Assessed by the Dermatology Quality of Life IndexTime frame: Baseline, 6 months, 1 Year
- Social Phobia as Assessed by the Social Phobia Inventory (SPIN)Time frame: Baseline, 6 months, 1 Year
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Johns Hopkins University
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.